Immunotherapy for head and neck cancer: a paradigm shift from induction chemotherapy to neoadjuvant immunotherapy
H Shibata, S Saito, R Uppaluri - Frontiers in Oncology, 2021 - frontiersin.org
Neoadjuvant immunotherapy has the potential to enhance clinical outcomes by increasing
anti-tumor immune responses in the presence of abundant tumor-derived antigen in an …
anti-tumor immune responses in the presence of abundant tumor-derived antigen in an …
Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine
H Zaryouh, M Vara-Messler, J Vignau… - Drug Resistance …, 2022 - Elsevier
Squamous cell carcinoma of the head and neck (SCCHN) is among the most prevalent
cancer types worldwide. Despite multimodal therapeutic approaches that include surgical …
cancer types worldwide. Despite multimodal therapeutic approaches that include surgical …
A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma
W Ju, R Xia, D Zhu, S Dou, G Zhu, M Dong… - Nature …, 2022 - nature.com
Novel neoadjuvant therapy regimens are warranted for oral squamous cell carcinoma
(OSCC). In this phase I trial (NCT04393506), 20 patients with locally advanced resectable …
(OSCC). In this phase I trial (NCT04393506), 20 patients with locally advanced resectable …
Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local–regionally advanced head and neck squamous cell carcinoma
TM Wise-Draper, S Gulati, S Palackdharry… - Clinical Cancer …, 2022 - AACR
Purpose: Patients with resected, local–regionally advanced, head and neck squamous cell
carcinoma (HNSCC) have a one-year disease-free survival (DFS) rate of 65%–69% despite …
carcinoma (HNSCC) have a one-year disease-free survival (DFS) rate of 65%–69% despite …
[HTML][HTML] Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer
JM Redman, J Friedman, Y Robbins… - The Journal of …, 2023 - Am Soc Clin Investig
BACKGROUND Head and neck squamous cell carcinoma not associated with HPV (HPV-
unrelated HNSCC) is associated with a high rate of recurrence and poor survival …
unrelated HNSCC) is associated with a high rate of recurrence and poor survival …
Tadalafil enhances immune signatures in response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma
AJ Luginbuhl, JM Johnson, LA Harshyne… - Clinical Cancer …, 2022 - AACR
Purpose: We hypothesize that the addition of the phosphodiesterase-5 inhibitor tadalafil to
the PD-1 inhibitor nivolumab, is safe and will augment immune-mediated antitumor …
the PD-1 inhibitor nivolumab, is safe and will augment immune-mediated antitumor …
Introducing checkpoint inhibitors into the curative setting of head and neck cancers: lessons learned, future considerations
The emergence of immunotherapy, in the form of immune checkpoint inhibitors, has
irrevocably altered the paradigm of cancer treatment over the past decade. Multiple …
irrevocably altered the paradigm of cancer treatment over the past decade. Multiple …
Less is more: Exploring neoadjuvant immunotherapy as a de-escalation strategy in head and neck squamous cell carcinoma treatment
LM Cao, NN Zhong, Y Chen, ZZ Li, GR Wang, Y Xiao… - Cancer Letters, 2024 - Elsevier
Head and neck squamous cell carcinoma (HNSCC) constitutes a significant global cancer
burden, given its high prevalence and associated mortality. Despite substantial progress in …
burden, given its high prevalence and associated mortality. Despite substantial progress in …
[HTML][HTML] Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!
M Maio, C Blank, A Necchi, AM Di Giacomo… - European Journal of …, 2021 - Elsevier
Abstract The Italian Network for Tumor Biotherapy (Network Italiano per la Bioterapia dei
Tumori [NIBIT]) Foundation hosted its annual 2020 Think Tank meeting virtually, at which …
Tumori [NIBIT]) Foundation hosted its annual 2020 Think Tank meeting virtually, at which …
Shooting at moving and hidden targets—tumour cell plasticity and the notch signalling pathway in head and neck squamous cell carcinomas
J Kałafut, A Czerwonka, A Anameriç… - Cancers, 2021 - mdpi.com
Simple Summary Cancers in the head and neck region are often aggressive and poorly
respond to both irradiation or chemotherapy. Chemotherapy is currently limited by a small …
respond to both irradiation or chemotherapy. Chemotherapy is currently limited by a small …